Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Dianthus Therapeutics, Inc. - Common Stock (NQ: DNTH )

25.16 +1.20 (+5.01%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 12, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Dianthus Therapeutics, Inc. - Common Stock

What 5 Analyst Ratings Have To Say About Dianthus Therapeutics
Via Benzinga
DNTH Stock Earnings: Dianthus Therapeutics Misses EPS, Beats Revenue for Q1 2024
DNTH stock results show that Dianthus Therapeutics missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
What 5 Analyst Ratings Have To Say About Dianthus Therapeutics
Via Benzinga
Why Cutera Shares Are Trading Lower By Over 26%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Cutera, Inc. (NASDAQ: CUTR) fell sharply during Friday’s session after the company reported worse-than-expected fourth quarter adjusted EPS results. 
Via Benzinga
Decoding 4 Analyst Evaluations For Dianthus Therapeutics
Via Benzinga
Why Dianthus Therapeutics (DNTH) Stock Is Exploding Higher
Dianthus Therapeutics shares traded higher by 37% Monday. The company announced a $230 million private placement. 
Via Benzinga
Worthington Steel Posts Upbeat Results, Joins Summit Midstream Partners, FedEx And Other Big Stocks Moving Higher On Friday
U.S. stocks were mixed, with the Dow Jones index falling around 50 points on Friday. 
Via Benzinga
Topics Stocks
Exposures US Equities
DNTH Stock Earnings: Dianthus Therapeutics Beats EPS, Beats Revenue for Q4 2023
DNTH stock results show that Dianthus Therapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
DNTH Stock Earnings: Dianthus Therapeutics Reported Results for Q3 2023
Dianthus Therapeutics just reported results for the third quarter of 2023. 
Via InvestorPlace
Antibody Player Dianthus Therapeutics Has Potential Amid Active M&A Landscape in Complement-Focused Firms: Analyst
Wedbush initiated coverage on Dianthus Therapeutics Inc (NASDAQ: DNTH), noting its lead program DNTH103 as a well-positioned monoclonal antibody directed against the active form of the  
Via Benzinga
Dianthus' Monoclonal Antibody On Promising Pathway To Gaining The Upper Hand - Analyst
Raymond James initiated coverage on Dianthus Therapeutics Inc (NASDAQ: DNTH), a recent reverse merger with the old Magenta Therapeutics. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 28, 2023
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.